Key result
Quercetin lowers metabolic age by ~2 years and lengthens telomeres in elderly metabolic syndrome patients.
Why the study?
There was a lack of literature data on the quercetin effect on endogenous cardiovascular risk factors and ageing biomarkers in elderly patients with metabolic syndrome.
Does quercetin improve endogenous cardiovascular risk factors and ageing biomarkers in elderly patients with metabolic syndrome?
RCT (n=110)
No
Does quercetin improve endogenous cardiovascular risk factors and ageing biomarkers in elderly patients with metabolic syndrome?
Absolute Event Rate: -2.26% vs -0.7%
p-value: p=<0.01
A 3-month course of quercetin may offer geroprotective benefits and improve cardiovascular risk profiles in elderly patients with metabolic syndrome.
May support adjunctive quercetin use in metabolic syndrome; hypothesis-generating, requiring RCTs before practice change.
The reason for this study was the lack of literature data on the quercetin effect on endogenous cardiovascular risk factors and ageing biomarkers in elderly patients with metabolic syndrome (MS). The results of this study showed that quercetin has a favourable corrective effect on endogenous cardiovascular risk factors in elderly patients with MS, quercetin course increases the resistance of the elderly to the effects of hypoxia, long-term quercetin use (within 3 months) leads to lengthening of telomeres and a decrease in metabolic age, which indicates the presence of a geroprotective effect. The obtained results of the quercetin course application influence on the telomere length show the expediency of continuing the study of this drug as an effective geroprotective agent.
No takes yet. Share an insight, caveat, or question.
Shatilo et al. (2022) conducted an RCT in Metabolic syndrome (n=110). Quercetin vs. Placebo was evaluated on Change in metabolic age (years) (p=<0.01). Quercetin administration of 240 mg daily for 3 months significantly decreased metabolic age by 2.26 years and lengthened leukocyte telomeres in elderly patients with metabolic syndrome.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: